The whole point of microdosing is gradual escalation
The dose of semaglutide used in this study was based on the highest clinically applicable dose of 2.4 mg, as determined by clinical trial data [45]
As noted earlier, CVS Caremark struck a deal with Novo Nordisk in late 2024: Wegovy was made the preferred GLP-1 on CVSs national formulary in exchange for discounts ( [61] )
MACE-5 (all-cause death, MI, stroke, heart failure event, coronary revascularisation) 44 events on retatrutide, 52 on placebo: In-study: HR 0.82 (95% CI 0.551.22) On-treatment: HR 0.73 (95% CI 0.471.12) MACE-3 (CV death, MI, stroke) 27 events on retatrutide, 23 on placebo: In-study: HR 1.12 (95% CI 0.641.96) On-treatment: HR 0.92 (95% CI 0.511.65) Lilly states plainly that MACE occurred less frequently than anticipated in both arms
A common mistake is confusing 60 units with the 6 mg dose at this concentration, then continuing to draw 60 units after switching to a different concentration vial where 60 units no longer equals 6 mg